Jun-Ichi Abe, Masaki Imanishi, Shengyu Li, Aijun Zhang, Kyung Ae Ko, Venkata S K Samanthapudi, Ling-Ling Lee, Angelica Paniagua Bojorges, Young Jin Gi, Brian P Hobbs, Anita Deswal, Joerg Herrmann, Steven H Lin, Eduardo N Chini, Ying H Shen, Keri L Schadler, Thi-Hong-Minh Nguyen, Anisha A Gupte, Cielito Reyes-Gibby, Sai-Ching J Yeung, Rei J Abe, Elizabeth A Olmsted-Davis, Sunil Krishnan, Robert Dantzer, Nicolas L Palaskas, John P Cooke, Henry J Pownall, Momoko Yoshimoto, Keigi Fujiwara, Dale J Hamilton, Jared K Burks, Guangyu Wang, Nhat-Tu Le, Sivareddy Kotla
BACKGROUND: ERK5 (extracellular signal-regulated kinase 5) is a dual kinase transcription factor containing an N-terminal kinase domain and a C-terminal transcriptional activation domain. Many ERK5 kinase inhibitors have been developed and tested to treat cancer and inflammatory diseases. However, recent data have raised questions about the role of the catalytic activity of ERK5 in proliferation and inflammation. We aimed to investigate how ERK5 reprograms myeloid cells to the proinflammatory senescent phenotype, subsequently leading to atherosclerosis...
June 2, 2023: Circulation Research